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Abstract Here we give an overview of a worldwide effort, called the ENIGMA
Consortium (http://enigma.ini.usc.edu), which unites scientists worldwide to deter-
mine how variants in our genetic code influence the brain, and how 12 major diseases
affect the brainworldwide.At the timeofwriting,ENIGMAinvolves over 500 scientists
from 185 institutions worldwide, working together on around 30 projects to discover
factors that may help or harm the brain. By pooling genome-wide genomic data and
brain imaging from over 33,000 people, ENIGMA has been able to identify single-
nucleotide differences in the genome that are associatedwith differences in human brain
structure and function. Given the broad interest in brain connectivity and the factors that
affect it, we outline some tactics adopted by ENIGMA to discover specific genes that
affect the brain; thenwe describe howENIGMA is extending thesemethods to discover
genetic influences on brain connectivity.
Background to ENIGMA
ENIGMA (Enhancing Neuroimaging Genetics through Meta-Analysis) is a world-
wide network of researchers who work together to investigate various questions
about the brain. The consortium pools brain imaging and genetic data from over
200 institutions around the world. The main goals of ENIGMA are to discover
factors that help and harm the brain; the sheer size of the dataset is unprecedented,
making it possible to see which effects on the brain are robust and consistent by
pooling data worldwide. The idea for ENIGMA originated in late 2009 and the
consortium has since published some of the largest brain imaging studies in the
world—both in terms of the total number of individuals genotyped and scanned
(now over 33,000) and in terms of the number of scientists collaborating [several
hundred co-authors, in Stein et al. (2012), Thompson et al. (2014), and Hibar et al.
(2015)]. Also, by pooling brain imaging and genomic data from tens of thousands of
people, we were able to overcome several technical and sociological barriers; here
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we outline some of the strategies employed and the main findings and lessons
learned. As befits a chapter in a book on brain connectivity, we also summarize the
tactics that ENIGMA is beginning to employ to discover genetic influences on brain
connectivity.
Genetic Influences on the Brain
By 2009, nearly 100 studies had been published showing that numerous measures
of brain structure are heritable (Blokland et al. 2012). In other words, individual
differences in our genetic code do affect specific features of the brain, such as the
overall volume of the brain, the size of the hippocampus, and even measures of
functional activity based on EEG or functional MRI. To establish this, researchers
began by studying family-based cohorts or twins who were scanned with anatom-
ical or functional MRI; when people with greater genetic similarity were compared,
their brains were found to be more similar, on average, than were unrelated people
of the same age and sex.
To formalize these ideas, the classical twin design has often been used to
estimate the heritability of a behavioral trait by studying both identical and fraternal
twins (siblings or other family members are often evaluated as well; Boomsma
et al. 2002). Based on structural equation models, or even based on simpler
approaches involving correlations, twin studies are able to estimate what fraction
of the observed variability in a brain measure is due to genetics, that is, due to the
genetic differences among individuals. Many measures of brain structure, such as
the total amount of gray or white matter in the brain or the overall volume of the
ventricles, were found to be heritable; that is to say, genetic factors are involved in
determining their eventual values. Note that this type of genetic analysis does not
require the direct examination of the DNA sequence, only the study of resem-
blances among family members with different degrees of familial relatedness (e.g.,
identical twins, siblings, etc.).
Soon afterwards, 3D “maps” of heritability began to be produced for a variety of
brain measures, such as regional gray matter volumes in the cortex (Thompson
et al. 2001), cortical thickness (Joshi et al. 2012), surface area (Chen et al. 2012),
and fiber microstructure in diffusion-weighted MRI scans (Chiang et al. 2009). The
proportion of variance due to genetic factors is not expected to be completely uniform
across the brain. In general, genetic variation accounts for around half of the observed
variance for many brain measures, in some cases more, making neuroimaging mea-
sures an attractive target for in-depth genetic analysis (Glahn et al. 2007).
The high heritability of brain structure is in line with many behavioral genetic
studies showing substantial genetic effects on behavior and even risk for neurolog-
ical and psychiatric illnesses, such as Alzheimer’s disease and schizophrenia.
Genetic studies have shown that numerous traits relating to personality, cognition,
and even risk for neurological or psychiatric disease are influenced by genetics to
some degree. The influence of genetic versus environmental factors on cognition
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and intellectual performance was one of the most hotly debated scientific topics of
the twentieth century (Jensen 1969; Lewontin et al. 1984). Of course, even if we
concede that genes play some role in behavior, several caveats to heritability
calculations apply: genetic variants do not influence the brain independently of
other factors, and their effects may depend on a person’s age, sex, level of nutrition,
education, or many other contextual factors in the population (Visscher et al. 2008).
Although they are not necessarily heritable, epigenetic factors, such as methylation
and acetylation, act on the genome to switch off or promote the action of certain
parts of our genetic code. Also, an individual’s environment may be correlated to
some degree with their genotype; for example, people with a natural aptitude for
certain kinds of activity may seek out environments that promote those activities.
This makes the effects of genes and environment difficult or impossible to disen-
tangle. Gene x Environment interactions are also found, where a gene’s effect on
the brain or behavior is accentuated or suppressed under certain conditions. In fact,
much work in the fields of pharmacogenomics and personalized medicine depends
on the notion that people with certain genetic risk factors may be less or more
responsive to medication or other kinds of therapy. As such, the quest to identify
genetic variants that relate to brain measures is likely to accelerate our genetic
understanding of brain disease and mental illness. With this in mind, ENIGMA has
several projects that relate brain measures to genomic variation and to disease, a
topic that we will return to later.
Finding the Genes Involved
Knowing that a brain measure is heritable—or influenced by genetic factors—is the
first step on the long road towards identifying specific differences in the genome
that influence it. By 2009, genetic “sequencing” had become relatively inexpensive,
and it was possible to reliably identify a person’s individual DNA sequence at each
of over one million genetic locations, based on a person’s blood or saliva sample.
Although well over 99 % of the genetic code is identical across healthy individuals,
people do differ substantially in specific areas of the genetic code: there are
deletions, expansions, and even single-nucleotide or single “letter” spelling differ-
ences in the base pair sequence. Some of these genetic differences do not affect the
protein product, if the gene is expressed at all. Other genetic differences render the
protein product dysfunctional or modify its activity, and they may influence brain
function and behavior and our risk for disease.
Genotyping companies began to offer genotyping services whereby over a
million common genetic variants—or single nucleotide polymorphisms (SNPs)—
could be assessed cheaply; in the United States, for example, some personalized
genomics companies offered to send a person a million “letters,” or nucleotides, of
their genetic code for $99 (in U.S. dollars). This ability to genotype common
variants in the genome led to a surge in the popularity of genome-wide association
studies (GWAS), efforts to identify markers or common variants in the human
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genome that are statistically associated with a certain trait, such as obesity, schizo-
phrenia, depression, or Alzheimer’s disease. Many of these genomic screens were
very successful. For instance, certain “risk genes,” such as APOE, CLU, and
TREM2, have alternative sequences wherein one form is more commonly found
in patients with Alzheimer’s disease (Harold et al. 2009; Jonsson et al. 2013). The
quest to find these risk-associated genetic variants is motivated by finding new drug
targets or, in the short term, evaluating a person’s risk for a specific disease, which
can help in clinical trial design.
Again, several caveats apply. Common variants are not the only source of
genetic variations that have an impact on the brain; in fact, rare variants—or even
private variants found only within a single family or individual—have been found
that associate with risk for autism or other disorders (Sanders et al. 2012; Purcell
et al. 2014). When GWAS was first feasible on a large scale, studies of tens of
thousands of individuals began to unearth common genetic differences associated
with cholesterol levels in the blood and with bone density, obesity, or stroke, and a
range of other common conditions. In each study, the genome was scanned for
sequence variations associated with a single trait, such as a person’s height, body
mass index, or a psychiatric diagnosis such as schizophrenia or bipolar illness, for
example. Because of the high risk of false positives—searching millions of letters
of the genetic code would likely detect many false associations—geneticists began
to enforce a very high statistical threshold to implicate a genetic variant in a
disorder, often requiring tens of thousands of subjects to find an association and
replicate it.
GWAS of the Brain
Around 2009, GWAS began to be performed on brain measures [see supplementary
information in Medland et al. (2014)], such as temporal lobe volume (Stein
et al. 2010). Although some of the top “hits” in these studies seemed convincing
from a mechanistic point of view, many geneticists argued that the power to detect
common genetic variants that affect the brain was very limited, even in samples of
approximately 1000 subjects. As brain imaging data are expensive and time-
consuming to collect, only the largest national initiatives could even achieve
sample sizes of 1000 subjects; the Alzheimer’s Disease Neuroimaging Initiative
(ADNI; Jack et al. 2008), for example, was one of the largest studies ever attempted
with neuroimaging. ADNI still took many years to recruit and scan a cohort of
800 people at 58 sites across North America. Power calculations suggest that
cohorts of 10,000 or more subjects should be needed to zero in on genomic regions
with reliable associations to brain measures, unless of course their effect sizes are
extremely large. And so began a debate as to whether imaging would offer a more
efficient way to detect influential genetic variants.
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Counterarguments and Power
Two arguments were commonly advanced to suggest that large samples might not
be required for successful genetic studies of brain images, but the evidence for each
argument began to wane. The first was that some image-derived measures might be
more highly reproducible than psychiatric diagnostic tests or cognitive scores; some
measures from images (such as the density of connections between brain regions)
might be closer to the biology of the gene action as well and therefore show a
stronger effect. For example, a growth factor gene, such as BDNF, might influence
the cell numbers or cell volumes in a specific structure of the brain, such as the
hippocampus. If so, then the statistical association between common variants
influencing the function of that gene and the size of the brain structure should be
fairly easy to identify in a database of brain scans. As we shall see, this optimism
had to be tempered; at least for the brain measures assessed so far, sample sizes
needed for successful genetic association studies have been about the same as those
needed to discover risk genes for clinical conditions such as Alzheimer’s disease or
schizophrenia, though less than those for major depression, and have been on the
order of tens of thousands. Even so, one should bear in mind that the large samples
required to detect effects does not mean effects are trivial or unimportant. Rare
variants with large effect, for example TREM2, appear to double a person’s risk for
Alzheimer’s disease (Guerreiro et al. 2013; Jonsson et al. 2013) and cause brain
tissue loss at twice the normal rate (Rajagopalan et al. 2013). Despite the fact that
only 1 % of people carry this risk allele, the aggregate effect on society is no doubt
substantial, perhaps similar to other mental disorders with similar prevalence but
with devastating impact.
A second argument was that we should focus on candidate genes when looking
for factors that affect the brain, rather than performing a completely open-ended,
genome-wide search. Because certain growth factors in the brain—BDNF, and
NGF, for example—have polymorphic variants within their genes, they could be
natural candidates for affecting volumes of the brain and perhaps other more subtle
features of brain function, such as functional activation or metabolism. Except for
major risk genes such as APOE, a risk factor for late-onset Alzheimer’s disease,
ENIGMA’s data would ultimately show that many of these candidate genes, long
thought to affect brain measures, did not appear to do so in much larger sample
sizes. This finding was confirmed in samples of 10,000 brain scans or more, samples
large enough to detect effects accounting for as little as 1 % of the variance in a
brain measure.
Between 2009 and 2012, over 20 cohorts worldwide came together to form
ENIGMA. The initial study (called “ENIGMA1”; Stein et al. 2012) found common
variants near the TESC gene that were associated with hippocampal volume
measured in MRI scans of the brain. The SNPs involved also affected gene
expression in living brain tissue, as confirmed by analysis of post-mortem brain
tissue. Carrying one form of the gene was associated with a hippocampal volume
that was smaller by an amount equivalent to about 3 years of brain aging, a small
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but substantial effect on a brain scan; the possible cognitive effects of this genetic
change, and their effects on disease risk, are now the target of study. Other findings
of ENIGMA1 included an association between intracranial volume in healthy
subjects and a genetic variant in HMGA2, a gene that had formerly been associated
with height and whose role in cell proliferation was beginning to be understood.
ENIGMA would not have been able to demonstrate that these associations were
robust without the help of another large consortium, CHARGE (Cohorts for Heart
and Aging Research in Genomic Epidemiology), whose GWAS studies of the aging
brain in five large elderly cohorts were crucial in establishing the generality of the
findings. In fact, when the two consortia exchanged their top findings for genetic
variants associated with hippocampal and intracranial volumes, their top five hits
were the same. The most associated SNPs in each consortium were the same ones,
even though the studies assessed different individuals and were designed indepen-
dently (Bis et al. 2012).
Non-biological Information Arising from ENIGMA
After ENIGMA’s first study, some hypotheses had to be revised about which genes
might affect brain measures and how easy it would be to detect their effects. Some
of the “hallowed” candidate genes in psychiatric genetics—COMT, for example—
were initially hailed as explaining a fair proportion of the risk for psychiatric
illness, only to be found less relevant or not well supported in follow-up studies
[see Button et al. (2013) for an analysis of this “winner’s curse” effect]. Perhaps for
the same reasons, many genes expected to influence brain structure were not found
to do so, even in ENIGMA’s highly powered study. Only APOE had a convincing
effect on hippocampal volume, with many growth factors and common psychiatric
risk genes not showing demonstrable effects in much larger sample sizes than
previously studied. Although it is not possible to rule out an effect that is
undetected, the effects of these genes would likely be less than 1 % of the measured
variance, much smaller than some originally thought.
On the bright side, the power to replicate findings across the whole diverse range
of cohorts and populations in ENIGMA was surprising and encouraging. Most
studies contributing to ENIGMA were designed with other goals in mind, on
different scanners and some on different continents. As the data were pooled after
the fact, substantial work went into showing that reproducible and accurate mea-
sures could be made of the same brain regions across sites and scanners [see
Supplemental Materials in Stein et al. (2012)]. On the genomic side, ENIGMA’s
use of reference panels such as HapMap3 and the 1000 Genomes datasets to
“impute” genetic data collected from different genotyping chips also made it
possible to pool data across sites, attaining a power not previously imagined for a
brain imaging study.
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But Do the ENIGMA Genes Affect Disease Risk?
Shortly after the initial study was published, a second initiative was started to screen
the genome for common variants associated with volumes of seven other subcor-
tical structures (the project was called “ENIGMA2”; Hibar et al. 2015) and 34 other
cortical structures (ENIGMA3; in progress). In the course of these studies, a
collaborative partnership began with the Psychiatric Genomics Consortium
(PGC) to see if any of the brain-relevant genes were “enriched” in the PGC’s
own screens for genes associated with psychiatric illnesses such as schizophrenia.
ENIGMA studies of schizophrenia, epilepsy, obsessive compulsive disorder, and
Alzheimer’s disease are currently underway. There is some optimism that these
enrichment analyses may show that some of the same genes that affect the structure
of the brain also create risk for disease. Several disease risk genes are known to be
convincingly associated with brain differences: many of the top 20 or so
Alzheimer’s risk genes (according to alzgene.org) are associated with differences
in brain structure, metabolism, or pathology identifiable with brain imaging. Some
of the logistics involved in looking up ENIGMA’s genes in other psychiatric
GWAS involves performing “checksum” tests to exclude people who have taken
part in both GWAS studies; such participants could cause spurious associations,
making it important to screen out non-independent data.
In parallel, ENIGMA launched several working groups to identify brain mea-
sures that showed the greatest patient vs. control differences in cohorts of patients
with schizophrenia (Turner et al. 2014; van Erp et al. 2015), bipolar illness (Hibar
et al. 2014), depression (Schmaal et al. 2014, 2015), and ADHD (Hoogman
et al. 2014). Some of these studies now number 4000–8000 subjects, making
them the largest studies ever of their respective disorders. Clearly, the power to
identify correlates of behavioral and cognitive dysfunction, and relevant modula-
tors of illness such as medication effects, makes these efforts highly informative.
All these studies are in their earlier phases now, but ultimately they may yield new
sources of information to distinguish psychiatric profiles based on brain imaging
and genetics and for differential diagnosis and even perhaps prognosis.
Searching Brain Images for Statistical Effects
In brain imaging studies more generally, it is common to align a group of subjects’
images to a standardized coordinate space and try to find parts of the brain with
consistent activations or brain regions whose activity relates to modifiable param-
eters of the experimental design. One such approach, called statistical parametric
mapping, or SPM, can identify brain regions where brain signals relate to some
external predictor, such as a task performed in the scanner, or psychiatric diagnosis.
To do this, often a regression model is fitted at thousands to millions of different
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locations in a 3D brain image and the significant regions are shown, after some
suitable correction for the multiple statistical tests made in the image.
Brain-Wide Genome-Wide Scanning
Although it may seem a daunting task, Stein et al. (2010) proposed a method to
screen every voxel (location) in the brain and every genotyped variant in a genomic
screen to search both images and genomes at once for promising associations. The
sheer number of computations can exceed one billion statistical tests. The first such
efforts found no genuinely replicated associations and were computationally feasi-
ble only on a massively parallel computer cluster.
Due to the massive number of statistical tests, the significance threshold that
needs to be achieved to control for false positives is around a billion to one (see
Medland et al. 2014). Even so, this threshold was achievable and far exceeded by
several “hits” (i.e., genetic associations) in ENIGMA2, making the approach
feasible statistically as well. Although voxel-wise GWAS is a tour de force com-
putationally, it can be combined with other techniques for dimension reduction to
focus the search on promising signals. These methods can be statistical, based on
genetic clustering or prioritizing brain measures with highest heritability, or they
can be based on biology and known genetic pathways. Such efforts are reviewed in
Thompson et al. (2013, 2014, 2015).
Genetic Screening of the Connectome
Based on the power that has been achieved so far through ENIGMA to discover
common genetic influences on brain structure, it should now be clear that genome-
wide analysis can also be extended to measures beyond that of individual neuro-
anatomical structures to discover factors that influence how regions of the brain are
connected or work together, i.e., measures of brain connectivity. Brain connectivity
can be modeled in terms of networks describing how different regions of the brain
function together (functional connectivity) or how they are physically connected in
terms of the strength, integrity, or pattern of the white matter fibers (structural
connectivity) (Fig. 1).
Family and twin studies found that specific connections and global organiza-
tional measures are heritable in both functional and structural networks. Glahn
et al. (2010) found that the resting state functional network, derived from blood
oxygen level-dependent functional MRI imaging, is remarkably heritable; Smit
et al. (2010) used EEG-based measures of connectivity to study the heritability of
measures of network “clustering” and path length. Fornito et al. (2011) examined
local and global measures of efficiency and connection distance, along with overall
density for resting state networks. In a similar investigation of functional
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connectivity in children, however, van den Heuvel et al. (2013) did not detect
significant heritability for certain local measures while robustly finding that more
global measures of network organization were heritable. Structural connectivity
and patterns of organization are also influenced by genetic factors. Jahanshad
et al. (2013b) showed that a fraction of the total number of detected connections
are indeed highly heritable, while Bohlken et al. (2014) studied the network’s
topology to establish heritability for other global measures of fiber connections.
The genetic influences on these brain measures have also been established by
exploring the effect of known disease risk genes on the connectome. Candidate
gene analyses have even suggested that connectome properties may be associated
with genetic risk factors for diseases and disorders such as autism (Scott-Van
Zeeland et al. 2010; Dennis et al. 2011), schizophrenia (Braskie et al. 2012), and
dementia (Brown et al. 2011; Jahanshad et al. 2012); given the history of candidate
gene associations in psychiatric genetics, these findings will need to be replicated
Fig. 1 Various forms of connectivity measures extracted from brain images; all these methods
allow us to study the brain from a higher dimensional perspective and observe correlations and
connections between regions. In the more classical approaches, voxelwise maps of activity or
DTI-based integrity measures can be mapped out. In addition to MRI-based imaging, electrodes
can be placed around the brain to obtain functional activation or electrophysiological signals.
Structural or functional connections between different regions can be estimated. A broad search
over all possible connections can lead to mapping the information in a matrix to form a mathe-
matical graph representation. Global properties of this matrix can then be thought of as measures
that describe the network as a whole. For example, one measure of interest examines the shortest
path lengths in the network or the paths with the lowest numbers of connections between one
region, or node, and all the others
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and assessed in larger samples. There is clear potential for using connectivity
measures as targets for genetic analysis or perhaps even for successfully discover-
ing disease risk genes through a genome-wide search.
While functional connectivity measures also appear to be promising targets for
genetic study, here we focus our discussion on expanding structural connectivity
analyses for large-scale genetic analyses in ENIGMA. Figure 2 shows the structural
connectivity matrix from an individual: it stores information on the proportion of
detected fibers connecting each pair of brain regions. Jahanshad et al. (2013a, b)
proposed a method to map structural connectivity based on diffusion-weighted MRI
and prioritize the resulting connections for a genome-wide screen to identify
common variants that affect brain connectivity. Not all possible connections are
found in all individuals and not all parts of the brain are directly connected to all the
others, so the connectivity matrices are relatively sparse (see Fig. 2). As such, a
matrix that represents some measure of the quality or density of connections
between all pairs of regions on the cortex may represent a number of possible
connections that is equal to the square of the number of regions, in theory. For
example, breaking up the cortex into 70 regions (Desikan et al. 2006) would lead to
a connectivity matrix of almost 5000 elements, but only around 1 % of these might
show high reproducibility and heritability in a population.
Using a classical twin model based on identical and fraternal twins, Jahanshad
et al. (2013a, b) identified the heritable connections within structural connectivity
Fig. 2 The structural connectivity matrix. Using standard anatomical MRI and a variant called
diffusion-weighted MRI for fiber tracking, we can map out the structural connectivity network of
the brain. To do this, we combine a cortical parcellation (top left) with a set of fiber pathways
computed using tractography algorithms (bottom left). The resulting connections between all pairs
of cortical regions are organized into a connectivity matrix (right). Its rows and columns corre-
spond to the cortical regions and the magnitudes of the elements represent properties of the
connections detected between them, such as fiber integrity or density
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matrices of several thousand elements and carried forward only the approximately
50 heritable connections into a genome-wide screen. The gene showing a genome-
wide and connectome-wide level association with a particular connection within the
connectome, SPON1, was subsequently also associated with cognitive decline in an
independent study, albeit at a different locus (Sherva et al. 2014). This gene is also
implicated in amyloid processing (Hafez et al. 2012), a key component of
Alzheimer’s disease pathology.
Clearly, the ability to pursue such an approach on a large scale, within
ENIGMA, depends on several factors: a working group, ENIGMA-DTI, was set
up to assess its feasibility. First, unless diffusion-weighted MRI measures show
greater genetic effect sizes than other traits assessed so far, there must be tens of
thousands of DTI scans available from people with GWAS for such a study to be
well powered. Second, the format of the connectivity matrix must be sufficiently
standardized and agreed on in advance, to allow the exchange and pooling of brain
connectivity data across sites.
Encouragingly, by mid-2014, the ENIGMA-DTI working group had amassed
around 10,000 DTI scans. Pilot studies showed that the data could be analyzed in a
consistent way (Jahanshad et al. 2013a; Kochunov et al. 2014). As the ENIGMA3
project involves a cortical volumetric analysis, the current plan is for ENIGMA to
use those cortical regions as the basis for a structural connectivity analysis, using
the same voxel-wise analysis of the connections as advocated in Stein et al. (2010)
and Jahanshad et al. (2013b). It will be interesting to see if similar sample sizes, tens
of thousands, are needed to find and replicate genetic associations with measures of
structural brain connectivity. It could be that mathematical tactics for dimension
reduction, or network-based measures, are also attractive targets for genetic anal-
ysis; so far the relative merits of each of these measures remains to be seen.
Caveats for Multi-site Genomic Analysis of the Connectome
In addition to the caveats noted for pooling multi-site structural MRI data, several
additional caveats make the analysis of connectivity challenging. First, the choice
of tractography methods can result in different matrices; the method only detects
fibers that the algorithm can identify, so many true connections may be missed and
some “false positive” connections will also be detected. As with standard MRI,
these factors are largely influenced by the signal to noise ratio and resolutions of the
images. Often, an arbitrary threshold is implemented to remove the false positive
connections, but short fibers can be filtered out. If a connection appears to be weak
or inconsistent across subjects, this connection may also be removed. Interestingly,
Fornito et al. (2011) found that, for resting state networks at different thresholds, the
degree of heritability varied for different global measures, and heritability was not
uniform across all nodes; there were various levels of genetic influence for each
measure. Lastly, while seemingly intuitive, the results do depend on the
parcellation of the cortex, the way the cortical surface is split up into regions of
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interest. Depending on the goals of the study, parcellation schemes can be improved
to maximize power.
Before embarking on large-scale collaborative efforts combining connectivity
matrices and network metrics, confounding factors such as these should be properly
investigated as is currently being done in ENIGMA’s working groups, such as the
ENIGMA-DTI and EEG working groups, among others. For example, in single site
studies, Buchanan et al. (2014) performed test-retest reliability analyses to explore
the reliability of measures after exploring a variety of commonly used approaches.
Dennis et al. (2012) and Zhan et al. (2013) explored the consequences of altering
the thresholds used to define networks as well as different methods of tractography,
respectively.
Future Directions: Adaptive Connectomics and EPIC
In Prasad et al. (2014), we introduced a method called “EPIC” (Evolving Partitions
in Connectomics) to compute brain connectivity in such a way as to be optimally
sensitive to statistical effects in a population, such as the effect of Alzheimer’s
disease or depression. Clearly, the brain can be divided into regions in many
different ways, such as spectral clustering (Craddock et al. 2012), hierarchical
clustering (Blumensath et al. 2013), or even genetic clustering (Chen et al. 2012).
Each one leads to a different definition of brain connectivity between the resulting
regions. Although the set of possible partitions is truly astronomical in number,
EPIC offers a principled approach to identify the optimal set of brain regions to find
specific statistical effects on the connectivity of the resulting regions. Put another
way, if we are seeking brain regions whose connectivity is disrupted in Alzheimer’s
disease, the algorithm will merge and split parts of the brain until it reaches a set of
connections that best differentiates Alzheimer’s disease patients from controls.
With this adaptive method in mind, it is easy to see how the brain could be
partitioned in such a way to maximize the heritability of the connections, automat-
ically de-selecting unfavorable measures before performing a genome-wide screen.
If that were done, genomic screens of the connectome might be more efficient,
allowing a two-way interplay between discovered genes and the search for connec-
tions they might affect.
Still further potential is available once a genome-wide hit is detected; in that
case, it should be possible to merge and split cortical sectors so that the genetic
effect of a SNP or set of SNPs is more powerfully detected. In other words, one
could adjust the cortical partition to maximize the proportion of variance that can be
attributed to SNPs or common genetic variants. These high-dimensional searches of
the connectome and genome at once will draw upon the full breadth of ingenuity of
mathematicians and geneticists alike.
With the scale of ENIGMA and other consortia now planned, it seems likely that
we may crack the “Enigma code” of the brain’s connectivity network, using
intelligent algorithms and the concerted efforts of the worldwide scientific
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community. Identifying the genetic influences on the structure and function of the
human brain can allow us to understand what makes us human and help uncover the
mechanisms causing psychiatric illness.
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